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Background: The aim of this study was to determine physicians’ opinion regarding pharmacovigilance feedback
sessions. A survey was conducted in a teaching hospital, and the physicians who attended the sessions were
invited to participate by filling out a structured questionnaire. All sessions included a review of adverse drug
reactions identified at the hospital and information on pharmacovigilance issues (news on warnings released by
regulatory agencies or drug toxicity problems identified by recently published studies in medical journals). The
survey questions were related to the interest, satisfaction, and belief in the utility of the sessions. A Likert scale
(0-10 points) was used to assess physicians’ opinions.
Findings: A total of 159 physicians attended the sessions and 115 (72.3%) participated in the survey. The mean
(SD) age was 38.9 (12.1) years, and 72 (62.6%) were men. The mean (SD) scores of interest, satisfaction with the
information provided, and belief in the utility of these sessions were 7.52 (1.61), 7.58 (1.46), and 8.05 (1.38)
respectively. Significant differences were observed among physicians according to medical category and speciality
in terms of interest, satisfaction, and belief in the utility of those sessions.
Conclusions: Educational activities for physicians, such as feedback sessions, can be integrated into the
pharmacovigilance activities. Doctors who attend the sessions are interested in and satisfied with the information
provided and consider the sessions to be useful. Additional studies on the development and effectiveness of
educational activities in pharmacovigilance are necessary.
Background
Spontaneous reporting of adverse drug reactions
(ADR) is an important method of post-marketing sur-
veillance [1,2]. However, spontaneous ADR reporting is
underused by physicians in primary health care and in
hospitals [3,4], and there is a need to promote pharma-
covigilance activities. Several interventions to solve the
problem of under-reporting of ADRs have been pro-
posed [5]. Some studies have evaluated the effective-
ness of educational interventions aimed at increasing
reporting among physicians [6-11]. However, there are
no studies assessing the doctors’ opinions about regu-
lar educational activities related to pharmacovigilance
issues. We previously reported our experience related
to an educational activity program that included regu-
lar pharmacovigilance sessions in different hospital
departments intended to increase awareness about
pharmacovigilance, to report on pharmacovigilance
issues, and to promote spontaneous ADR reporting
[11]. The aim of our study was to understand hospital




A voluntary, anonymous survey was conducted among
doctors working at a teaching hospital in order to assess
their opinion regarding the development of the regular
pharmacovigilance sessions as part of the Pharmacovigi-
lance Programme (PhVP) at the hospital. The survey
was carried out from 8 February to 10 March 2006; all
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participate.
Session content
The pharmacovigilance sessions were held during sched-
uled staff sessions and lasted about 45 to 60 minutes to
ensure that the greatest number of physicians could be
present. The groups were made up of a variable number
of physicians. The presentations were given by clinical
pharmacologists and divided into three parts. The first
part included a review of all identified and reported
ADRs throughout the hospital (number of cases, type
and severity of ADR, type of drug) between 1 January
2003 and 31 December 2005. The second part included
a review of identified and reported ADRs in each speci-
fic medical department where the sessions were held.
The main features of the cases and their contribution to
the overall results of the PhVP were openly discussed.
The third part provided general information on pharma-
covigilance issues such as signals generated by the
PhVP, news about ADR warnings released by regulatory
agencies (Spanish Agency of Medicinal and Health Care
Products, the European Medicines Agency, the U.S.
Food and Drug Administration, and others), or drug
toxicity problems identified by published studies in
medical journals, and all topics were discussed openly.
Variables
Information was collected on the number of physicians
who attended the session and the number of physicians
who answered the survey. The physicians were inter-
viewed using a structured questionnaire (one sheet in
Spanish) that included demographic variables (age, sex,
medical speciality, professional category) and asked
seven questions about the sessions. The first three ques-
tions were general items on interest in the sessions,
satisfaction with the information provided, and beliefs
regarding the utility of the sessions. The last four ques-
tions were related to specific interest in each part of the
presentation: review of ADRs observed throughout the
hospital, review of ADRs observed in their medical
department, information on signals generated by the
PhVP, and information related to news and warnings
released by regulatory agencies or published in the med-
ical journals. To assess the doctors’ opinions, a Likert
scale (0-10 points) was used.
Statistical analysis
For the descriptive analysis, continuous variables were
described by the mean, standard deviation (SD), median,
and range. The statistical differences between the mean
scores according to the medical specialities and profes-
sional categories were assessed by one-way analysis of
variance (ANOVA) and Bonferroni post-hoc multiple
comparison test. Categorical variables were described
with percentages and statistical differences were assessed
by the c
2 test. Significance was set at a level of 0.05
(two-tailed). The statistical analysis was performed using
the SPSS version 14.0 statistical package.
Results
A total of 159 physicians were present at the sessions,
and 115 (72.3%) participated in the survey. The mean
(SD) age was 38.9 (12.1) years, and 72 (62.6%) were
men. A total of 61 (53%) were staff physicians, and 54
(47%) were in training (residents). The mean (SD) age
of staff physicians was 47.9 (7.4) years, and 53 (86.9%)
of them were men. The mean (SD) age of residents was
28.6 (7.1), and 35 (64.8%) of them were women. The
medical specialities of the physicians who attended the
sessions and participated in the survey are shown in
Table 1.
The mean (SD) score of physicians’ interest in the ses-
sions was 7.52 (1.61) [median 8, minimum 0, maximum
1 0 ] .T h em e a n( S D )s c o r eo ft h ep h y s i c i a n s ’ satisfaction
with the information provided was 7.58 (1.46) [median
8, minimum 2, maximum 10]. The mean (SD) score of
physicians’ belief in the utility of these sessions was 8.05
(1.38) [median 8, minimum 4, maximum 10].
The mean (SD) score of physicians’ interest in PhVP
results was 7.38 (1.80) [median 8, minimum 0, maxi-
mum 10]. The mean (SD) score of physicians’ interest in
the pharmacovigilance results in their own departments
was 7.91 (1.80) [median 8, minimum 0, maximum 10].
The mean (SD) score of physicians’ interest in signals
generated by the PhVP was 7.63 (1.63) [median 8, mini-
mum 0, maximum 10]. The mean (SD) score of physi-
cians’ interest in news released by regulatory agencies or
identified by publications was 7.97 (1.44) [median 8,
minimum 4, maximum 10].
The mean scores for interest, satisfaction, and belief in
the utility of the sessions were higher for staff physicians
than for residents (Table 2). The mean score of interest
in the information provided was also higher for staff
physicians than for residents (Table 3). There were no
statistically significant differences among medical speci-
alities in the mean score of physicians’ interest whereas
the mean score of physicians’ satisfaction and the mean
score of physicians’ belief in the utility of the sessions
were statistically different among physicians with differ-
ent specialities (Table 4).
Discussion
The present study shows that most physicians who
attend the pharmacovigilance sessions at the hospital
are satisfied with them and consider them useful. The
regular sessions enhance the relationship between health
professionals responsible for the pharmacovigilance
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the sessions, the pharmacovigilance programme results
at the hospital are presented, and the news and warn-
ings about the risks of drug toxicities are discussed to
provide drug safety information to the medical staff.
Sessions are intended to increase physicians’ awareness
of pharmacovigilance topics and to explain the princi-
ples and demands of pharmacovigilance and the impor-
tance of reporting ADRs. Additionally, sessions improve
interaction between the physicians responsible for the
programme and those in the various specialities because
the time encourages dialogue, opinion-sharing, and clo-
ser professional contact. Thus, the development of regu-
lar pharmacovigilance sessions, together with other
interventions, has improved spontaneous ADR reporting
by hospital physicians [11]. Nevertheless, session pre-
paration is specific to each medical department and
requires considerable time and effort.
Pharmacovigilance activities are essential to ensure
that doctors have enough information to prescribe drugs
appropriately [12]. Health care professionals usually
have little basic knowledge of ADRs or the voluntary
reporting system [13,14]. Moreover, a lack of basic
knowledge about ADRs and health professionals’ atti-
tudes regarding the voluntary reporting procedure has
been associated with under-reporting [15]. Health care
professional education and training are needed to
improve the current ADR reporting system. Previous
experiences reported strategies in which spontaneous
ADR reporting is integrated with training and
continuous education [16]. Therefore, we decided that
our approach should integrate in-hospital ADR report-
ing with physician training and continuous education.
Educational interventions with feedback improve ADR
reporting by physicians in both primary health care [10]
and hospitals [11] and also enhance ADR reporting by
pharmacists [17]. Wallersted et al [18] reported that
most physicians stated that feedback content to doctors
reporting ADRs may influence ADR reporting rates. In
fact, a distance-learning pharmacovigilance programme
linked to educational credits was also associated with
improved reporting of suspected ADRs by general prac-
titioners and pharmacists [19]. In a Dutch survey, gen-
eral practitioners and specialists were asked about their
experiences and expectations regarding feedback infor-
mation from the pharmacovigilance centre. The feed-
back process contained information on whether the
reported ADR was described and on the causal relation-
ship between the drug and the ADR. Both general prac-
titioners and specialists were satisfied with the feedback
from the pharmacovigilance centre because they found
it reliable, scientifically sound, and highly valuable [20].
Educational activities in pharmacovigilance are necessary
not only for physicians but for other health care profes-
sionals. A Swedish study reported an increase in the
total number of ADR reports after pharmacovigilance
teaching sessions were held for interested nurses. These
results suggest that interested, well-instructed nurses
could also play an important role in identifying and
reporting suspected ADRs [21].
The development of ADR reporting and monitoring
systems in the hospital setting has been described [22].
Educational activities integrated in the hospital pharma-
covigilance programme are necessary to build a culture
of pharmacovigilance at the hospital and to raise aware-
ness of spontaneous ADR reporting. However, educa-
tional activities with periodic dissemination of
information have only been carried out on a few
occasions. In a previous study, we reported that contin-
uous intervention based on health care management
Table 1 Physician participation in the survey according to medical speciality
Medical speciality
(total number of physicians)
Physicians who attended the sessions
N (%)
Physicians who participated in the survey
N (%)
Internal medicine (65) 44 (67.7) 26 (40.0)
Cardiology (44) 38 (86.4) 19 (43.2)
Pulmonology (36) 20 (55.5) 18 (50.0)
Hepatology (17) 17 (100) 14 (82.3)
Infectious diseases (16) 16 (100) 14 (87.5)
Nephrology (29) 12 (41.4) 10 (34.5)
Other
a (52) 18 (26.5) 14 (20.6)
Total (275) 159 (57.8) 115 (41.8)
a Includes neurology, endocrinology, and dermatology.
Table 2 Physicians’ opinion of the pharmacovigilance
sessions according to medical category
Medical category Staff Residents P-value
Interest
Mean (SD)
8.25 (1.15) 6.70 (1.68) < 0.0001
Satisfaction
Mean (SD)
8.21 (1.11) 6.87 (1.48) < 0.0001
Utility
Mean (SD)
8.46 (1.19) 7.59 (1.45) 0.001
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with a quantitative and qualitative improvement in
spontaneous ADR reporting by hospital physicians [11].
T h ep r e s e n ts t u d yi st h ef i r s tt oa s kp h y s i c i a n sa b o u t
the development of pharmacovigilance educational activ-
ities at the hospital. The hospital’s doctors valued the
regular pharmacovigilance sessions positively, although
we observed some differences among those interviewed,
as staff physicians were more interested in the sessions
than residents in training. The reasons for these differ-
ences are unknown, but perhaps medical staff is more
familiar with the pharmacovigilance programme while
residents are more interested in other topics of their
medical specialisation. These results suggest that addi-
tional effort and research in pharmacovigilance educa-
tion are needed to draw the interest of physicians still in
training. Satisfaction and belief in the utility of sessions
(but not in interest in sessions) differed according to
medical speciality, in particular, they were higher in
internal medicine than other medical specialities,
although there are no other similar studies with which
we can compare our results. In a previous study, specia-
lists were more likely to expect information on ADRs
than general physicians [20]. Future studies should
investigate speciality-related differences linked to phar-
macovigilance educational activities.
The main limitations of our study were the low num-
ber of doctors who attended the sessions and partici-
p a t e di nt h es u r v e ya n dt h ep r o b l e mw i t he x t r a p o l a t i n g
our results to other settings. The study was conducted
at the largest tertiary teaching hospital in Catalonia,
which has a long tradition in pharmacovigilance activ-
i t i e s .T h es e s s i o n sw e r eo n l yc o n d u c t e df o rs o m em e d i -
cal specialities. Therefore, we do not know whether
other settings or medical specialities would yield similar
results. Other limitations are the reliability of answers
-an inherent problem of surveys and interviews- and
whether the physicians’ answers are truly representative.
Despite these limitations, our study provides informa-
tion on hospital doctors’ opinion about pharmacovigi-
lance educational activities. Future studies should
confirm these results in other settings and investigate
the influence of the different types of educational activ-
ities on physicians’ opinion. The survey could also be
used to assess performance in the context of pharma-
covigilance activities.
Conclusions
Pharmacovigilance educational and feedback sessions
with physicians can be integrated into hospital pharma-
covigilance activities. Physicians at our hospital stated
that the sessions are useful and interesting and that they
are satisfied with them. Further studies on the develop-
ment and effectiveness of pharmacovigilance activities
are necessary.
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